OPTN: OptiNose Company Aggregate Debts

Symbol and logo of brand OptiNose Inc (OPTN)

The financial stability of OptiNose, Inc. (OPTN) is confirmed by sufficient capital to meet all obligations, with the separate_debt metric standing at 0.00. The market trend, visualized in monetary terms, complements data on proprietary nasal devices that stimulate regular patient purchases due to their unique composition. High product quality is ensured by automated assembly lines, which eliminate human error in the creation of precision components.

OptiNose, Inc. - OPTN Company Debts (period 07/04/2022 - 05/31/2025)

Analytical breakdowns and data insights for company OptiNose (OPTN)

- price and consensus price forecast:
Price Performance Chart OptiNose Corp|OPTN - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Optinose|OPTN - Total Company Value
- book capitalization data:
Accounting Value of a Share OptiNose|OPTN - Company Book Value|Market Cap to Net Assets Ratio optinose.com|OPTN - Company Total Assets
- debt and liquidity data:
Total Debt to Capital OptiNose, Inc.|OPTN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital OptiNose Inc|OPTN - Company Debts|Debts to Book Value Optinose|OPTN - Company Long-Term Liabilities|Amount of Current Liabilities OptiNose
Fundamental company valuation:OPTN (OptiNose Corp)
Original product of OptiNose Inc

This indicator provides a real-time assessment of the ratio of total borrowings to the market value of net assets, allowing for an evaluation of the debt load and liquidity risks amid changes in borrowing costs. For OptiNose, Inc. (OPTN), which is scaling the distribution of XHANCE, the total debt figure reflects the intensity of capital raising for expansion within the ENT segment and the level of financial stability during this period of commercial growth.

Analysis of competing companies

Aggregate Debt Obligations Haleon Corp (HLN)|Company Aggregate Debts KVUE (Kenvue Inc.)|veronapharma.com - Company Aggregate Debts|Company Debts Jyong Biotech (MENS)|LGND: Aggregate Debt Obligations|AMRX (Amneal Pharmaceuticals Inc) - Company Debts|Perrigo Corp (PRGO) - Company Total Debt|ALVO (Alvotech) - Company Aggregate Debts|Company Aggregate Debts liquidia.com (LQDA)|Galapagos (GLPG) - Company Total Debt|Aggregate Debt Obligations ANIP (ANI Pharmaceuticals Inc)|MNKD: Company Debts|AMPH - Company Cumulative Debt|Company Total Debt Pacira BioSciences PCRX|SPRY - Company Cumulative Indebtedness|Company Aggregate Debts Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Aggregate Debt Obligations|Company Aggregate Debts SCPH (scPharmaceuticals, Inc.)|Company Cumulative Debt TECX|Tonix Pharmaceuticals (TNXP) - Company Debts|Aggregate Debt Obligations SXTC (sxtchina.com)|EPRX: Company Debts|BioHarvest Sciences, Inc. - Company Cumulative Debt|Company Debts Invizyne Technologies, Inc.|Oramed Pharmaceuticals (ORMP) - Company Aggregate Indebtedness|ENTX - Company Total Debt|ipatherapeutics.com (HYFT) - Company Cumulative Indebtedness|ABVC: Company Aggregate Debts|Company Total Debt Obligations CPIX|Company Debts Quantum BioPharma Limited QNTM|Company Aggregate Debt FGEN (FibroGen Corporation)|TELO: Company Debts|Rani Therapeutics Holdings - Company Cumulative Debt|Company Debts SNYR (Synergy CHC Corporation)|RLYB - Company Total Debt Obligations|Company Aggregate Debts LEXX|Company Cumulative Debt Pulmatrix Corporation|PTHL - Company Total Debt|Aggregate Debt Obligations Aptorum|LYRA (Lyra Therapeutics) - Company Aggregate Debts|Company Total Debt Obligations IBO (Impact BioMedical, Inc.)|TNFA - Company Debts|Company Aggregate Debt cbdMD Inc. YCBD|PRFX: Company Aggregate Debts|Altamira Therapeutics (CYTO) - Company Total Debt|Lipella Pharmaceuticals, Inc. - Company Total Debt|PIRS (Pieris Pharmaceuticals Inc) - Company Total Debt Obligations|Company Debts PROC (Procaps Group SA)|Company Cumulative Debt PTPI|QLI - Company Debts|Company Aggregate Indebtedness acelyrin.com SLRN|Company Total Debt TFF Pharmaceuticals, Inc. (TFFP)